The U.S. pharmaceutical wholesaler Cardinal Health Inc. has presented its financial results for the first quarter of 2012/13: according to the company, they achieved a revenue of $25.89 billion from the previous year of $26.79 billion (-3.36 percent). The net profit increased by 14.35 percent to double digits to $271 million with net income of $237 million on the same period last year.
The pharmaceutical division made the Dublin-based company $23.5 billion (-4 percent) and a profit before tax of $400 million for the major part. Revenue for the Medical segment increased by 1 percent to $2.4 billion. This was in part due to last year’s acquisition of Futuremed. Segment earnings declined 6 percent to $74 million.
They have benefited more than U.S. competitor of McKesson, mainly from the strong operating performance of the pharmaceutical division and further improved margins, said the company.
[ilink url=“http://ir.cardinalhealth.com/releasedetail.cfm?ReleaseID=717055″] Link zur Quelle (Cardinal Health)[/ilink]